Download PDF
Horm Metab Res 2005; 37: 26-34
DOI: 10.1055/s-2005-861360
Review
© Georg Thieme Verlag KG Stuttgart · New York

AGE-RAGE and AGE Cross-link Interaction: Important Players in the Pathogenesis of Diabetic Kidney Disease

L.  J.  N.  Jensen1 , J.  Østergaard1 , A.  Flyvbjerg1
  • 1 The Medical Research Laboratories, Clinical Institute and the Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark
Further Information

Publication History

Received 6 December 2004

Accepted after Revision 27 January 2005

Publication Date:
25 May 2005 (online)

Also available at
    Permissions and Reprints

Abstract

At present, diabetic kidney disease affects about 15 - 25 % of all type 1 diabetic patients and 20 - 40 % of all patients with type 2 diabetes. The mechanisms underlying the development of diabetic kidney disease are extremely complex and not yet fully understood. Among the many potential pathogenic mechanisms responsible for the progression in diabetic kidney disease, the involvement of metabolic factors beyond blood glucose (such as advanced glycation end products (AGEs)) has been suggested. This review will present the emerging evidence in support of a significant role of AGE formation in the development of diabetic kidney disease. AGEs mediate their effects through two main pathways - through a receptor-independent AGE cross-link formation pathway and through a receptor-dependent pathway where AGEs bind to specific cell surface associated receptors, the receptor for AGE (RAGE) being the most well-characterised so far. First, we will describe the AGE-RAGE system, including its localisation in the normal kidney, and then move on to discuss in vitro and in vivo studies (that is, experimental and clinical data) in support of a pathogenic role of AGE-RAGE and AGE cross-link interaction in the development of diabetic kidney disease. Finally, the effects of known and potential inhibitors of AGE-RAGE and AGE cross-link systems in diabetic kidney disease will be examined.

Key words

Diabetic nephropathy - TGF-β - CTGF - VEGF - PDGF - IGF-I - PKC - ROS - NF-κB - Aminoguanidine - Pyridoxamine - OPB-9195 - LR-90 - 2,3 diaminophenazine - Cross-link breakers - ALT-711 - ALT-946 - PTB - sRAGE - RAGE Antibody

References

  • 1 Marshall S M. Recent advances in diabetic nephropathy.  Postgrad Med J. 2004;  80 624-633
    CrossrefPubMedGoogle Scholar
  • 2 Rossing K, Christensen P K, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients.  Kidney Int. 2004;  66 1596-1605
    CrossrefPubMedGoogle Scholar
  • 3 Jude E B, Anderson S G, Cruickshank J K, Srivatsa A, Tentolouris N, Chandrasekaran R, Gokal R, Boulton A J. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes.  QJM. 2002;  95 371-377
    CrossrefPubMedGoogle Scholar
  • 4 The Diabetes Control and Complications Trial Study Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 978-986
    PubMedGoogle Scholar
  • 5 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 6 Newton C A, Raskin P. Blood pressure control-effects on diabetic nephropathy progression: how low does blood pressure have to be?.  Curr Diab Rep. 2002;  2 530-538
    PubMedGoogle Scholar
  • 7 Schrijvers B F, De Vriese A S, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.  Endocr Rev. 2004;  25 971-1010
    CrossrefPubMedGoogle Scholar
  • 8 Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease.  Am J Kidney Dis. 2001;  38 S100-S106
    PubMedGoogle Scholar
  • 9 Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S. Advanced glycation end products in clinical nephrology.  Kidney Blood Press Res. 2004;  27 18-28
    CrossrefPubMedGoogle Scholar
  • 10 Williams M E. New therapies for advanced glycation end product nephrotoxicity: current challenges.  Am J Kidney Dis. 2003;  41 S42-S47
    PubMedGoogle Scholar
  • 11 Schmidt A M, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.  J Biol Chem. 1992;  267 14 987-14 997
    PubMedGoogle Scholar
  • 12 Vlassara H, Palace M R. Diabetes and advanced glycation endproducts.  J Intern Med. 2002;  251 87-101
    CrossrefPubMedGoogle Scholar
  • 13 Wautier J L, Guillausseau P J. Advanced glycation end products, their receptors and diabetic angiopathy.  Diabetes Metab. 2001;  27 535-542
    PubMedGoogle Scholar
  • 14 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
    CrossrefPubMedGoogle Scholar
  • 15 Lassila M, Seah K K, Allen T J, Thallas V, Thomas M C, Candido R, Burns W C, Forbes J M, Calkin A C, Cooper M E, Jandeleit-Dahm K A. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.  J Am Soc Nephrol. 2004;  15 2125-2138
    CrossrefPubMedGoogle Scholar
  • 16 Tanji N, Markowitz G S, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt A M, D'Agati V D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.  J Am Soc Nephrol. 2000;  11 1656-1666
    PubMedGoogle Scholar
  • 17 Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole dS, Monnier V M, Witztum J L, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.  J Clin Invest. 1997;  100 2995-3004
    PubMedGoogle Scholar
  • 18 Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.  J Clin Invest. 1997;  99 1272-1280
    PubMedGoogle Scholar
  • 19 Oldfield M D, Bach L A, Forbes J M, Nikolic-Paterson D, McRobert A, Thallas V, Atkins R C, Osicka T, Jerums G, Cooper M E. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).  J Clin Invest. 2001;  108 1853-1863
    CrossrefPubMedGoogle Scholar
  • 20 Soulis T, Thallas V, Youssef S, Gilbert R E, McWilliam B G, Murray-McIntosh R P, Cooper M E. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.  Diabetologia. 1997;  40 619-628
    CrossrefPubMedGoogle Scholar
  • 21 Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt A M, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E. Expression of receptors for advanced glycosylated end-products in renal disease.  Nephrol Dial Transplant. 1995;  10 1662-1667
    PubMedGoogle Scholar
  • 22 Li J H, Huang X R, Zhu H J, Oldfield M, Cooper M, Truong L D, Johnson R J, Lan H Y. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.  FASEB J. 2004;  18 176-178
    PubMedGoogle Scholar
  • 23 Mason R M, Wahab N A. Extracellular matrix metabolism in diabetic nephropathy.  J Am Soc Nephrol. 2003;  14 1358-1373
    CrossrefPubMedGoogle Scholar
  • 24 Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, Cresci B, Galli G, Rotella C M, Vlassara H, Di Mario U. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism.  Diabetes. 1997;  46 1881-1887
    PubMedGoogle Scholar
  • 25 Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.  J Clin Invest. 2001;  108 261-268
    CrossrefPubMedGoogle Scholar
  • 26 Twigg S M, Cao Z, McLennan S V, Burns W C, Brammar G, Forbes J M, Cooper M E. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.  Endocrinology. 2002;  143 4907-4915
    CrossrefPubMedGoogle Scholar
  • 27 Skolnik E Y, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.  J Exp Med. 1991;  174 931-939
    CrossrefPubMedGoogle Scholar
  • 28 Ziyadeh F N, Han D C, Cohen J A, Guo J, Cohen M P. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system.  Kidney Int. 1998;  53 631-638
    CrossrefPubMedGoogle Scholar
  • 29 Throckmorton D C, Brogden A P, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products.  Kidney Int. 1995;  48 111-117
    PubMedGoogle Scholar
  • 30 Chen S, Cohen M P, Lautenslager G T, Shearman C W, Ziyadeh F N. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells.  Kidney Int. 2001;  59 673-681
    CrossrefPubMedGoogle Scholar
  • 31 Cohen M P, Ziyadeh F N, Lautenslager G T, Cohen J A, Shearman C W. Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells.  Am J Physiol. 1999;  276 F684-F690
    PubMedGoogle Scholar
  • 32 Kim Y S, Kim B C, Song C Y, Hong H K, Moon K C, Lee H S. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta.  J Lab Clin Med. 2001;  138 59-68
    CrossrefPubMedGoogle Scholar
  • 33 Scivittaro V, Ganz M B, Weiss M F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells.  Am J Physiol Renal Physiol. 2000;  278 F676-F683
    PubMedGoogle Scholar
  • 34 Yan S D, Schmidt A M, Anderson G M, Zhang J, Brett J, Zou Y S, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.  J Biol Chem. 1994;  269 9889-9897
    PubMedGoogle Scholar
  • 35 Lal M A, Brismar H, Eklof A C, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation.  Kidney Int. 2002;  61 2006-2014
    CrossrefPubMedGoogle Scholar
  • 36 Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells.  Kidney Int. 2003;  63 464-473
    CrossrefPubMedGoogle Scholar
  • 37 Tsuji H, Iehara N, Masegi T, Imura M, Ohkawa J, Arai H, Ishii K, Kita T, Doi T. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells.  Biochem Biophys Res Commun. 1998;  245 583-588
    CrossrefPubMedGoogle Scholar
  • 38 Huang J S, Guh J Y, Chen H C, Hung W C, Lai Y H, Chuang L Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.  J Cell Biochem. 2001;  81 102-113
    CrossrefPubMedGoogle Scholar
  • 39 Li J H, Wang W, Huang X R, Oldfield M, Schmidt A M, Cooper M E, Lan H Y. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.  Am J Pathol. 2004;  164 1389-1397
    PubMedGoogle Scholar
  • 40 Simm A, Munch G, Seif F, Schenk O, Heidland A, Richter H, Vamvakas S, Schinzel R. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1.  FEBS Lett. 1997;  410 481-484
    CrossrefPubMedGoogle Scholar
  • 41 Vlassara H, Striker L J, Teichberg S, Fuh H, Li Y M, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.  Proc Natl Acad Sci USA. 1994;  91 11 704-11 708
    PubMedGoogle Scholar
  • 42 Striker L J, Striker G E. Administration of AGEs in vivo induces extracellular matrix gene expression.  Nephrol Dial Transplant. 1996;  11 Suppl 5 62-65
    PubMedGoogle Scholar
  • 43 Yang C W, Vlassara H, Peten E P, He C J, Striker G E, Striker L J. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.  Proc Natl Acad Sci USA. 1994;  91 9436-9440
    PubMedGoogle Scholar
  • 44 Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes.  Kidney Int. 1998;  54 438-447
    CrossrefPubMedGoogle Scholar
  • 45 Shikata K, Makino H, Sugimoto H, Kushiro M, Ota K, Akiyama K, Araki N, Horiuchi S, Ota Z. Localization of advanced glycation endproducts in the kidney of experimental diabetic rats.  J Diabetes Compl. 1995;  9 269-271
    PubMedGoogle Scholar
  • 46 Niwa T, Katsuzaki T, Ishizaki Y, Hayase F, Miyazaki T, Uematsu T, Tatemichi N, Takei Y. Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes.  FEBS Lett. 1997;  407 297-302
    CrossrefPubMedGoogle Scholar
  • 47 Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, Niwa T. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.  Am J Kidney Dis. 2003;  41 S68-S71
    PubMedGoogle Scholar
  • 48 Bach L A, Dean R, Youssef S, Cooper M E. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy.  Nephrol Dial Transplant. 2000;  15 347-354
    PubMedGoogle Scholar
  • 49 Forbes J M, Cooper M E, Thallas V, Burns W C, Thomas M C, Brammar G C, Lee F, Grant S L, Burrell L A, Jerums G, Osicka T M. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.  Diabetes. 2002;  51 3274-3282
    PubMedGoogle Scholar
  • 50 Wendt T M, Tanji N, Guo J, Kislinger T R, Qu W, Lu Y, Bucciarelli L G, Rong L L, Moser B, Markowitz G S, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth P P, Stern D M, D"Agati V D, Schmidt A M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.  Am J Pathol. 2003;  162 1123-1137
    CrossrefPubMedGoogle Scholar
  • 51 Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.  Diabetes Metab Res Rev. 2002;  18 224-237
    CrossrefPubMedGoogle Scholar
  • 52 Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.  Diabetologia. 1999;  42 579-588
    CrossrefPubMedGoogle Scholar
  • 53 Rong J, Qiu H, Wang S. Advanced glycosylation end products, protein kinase C and renal alterations in diabetic rats.  Chin Med J (Engl). 2000;  113 1087-1091
    PubMedGoogle Scholar
  • 54 Adhikary L, Chow F, Nikolic-Paterson D J, Stambe C, Dowling J, Atkins R C, Tesch G H. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy.  Diabetologia. 2004;  47 1210-1222
    PubMedGoogle Scholar
  • 55 Li J H, Huang X R, Zhu H J, Oldfield M, Cooper M, Truong L D, Johnson R J, Lan H Y. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.  FASEB J. 2004;  18 176-178
    PubMedGoogle Scholar
  • 56 Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions.  J Am Soc Nephrol. 1999;  10 822-832
    PubMedGoogle Scholar
  • 57 Miyata S, Monnier V. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline.  J Clin Invest. 1992;  89 1102-1112
    PubMedGoogle Scholar
  • 58 Garlick R L, Bunn H F, Spiro R G. Nonenzymatic glycation of basement membranes from human glomeruli and bovine sources. Effect of diabetes and age.  Diabetes. 1988;  37 1144-1150
    PubMedGoogle Scholar
  • 59 Berg T J, Clausen J T, Torjesen P A, Dahl-Jorgensen K, Bangstad H J, Hanssen K F. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.  Diabetes Care. 1998;  21 1997-2002
    CrossrefPubMedGoogle Scholar
  • 60 Berg T J, Bangstad H J, Torjesen P A, Osterby R, Bucala R, Hanssen K F. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus.  Metabolism. 1997;  46 661-665
    CrossrefPubMedGoogle Scholar
  • 61 Schalkwijk C G, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers H G, Schlingemann R O, Tarnow L, Parving HH, Stehouwer C D, van Hinsbergh V W. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.  Diabetes. 1999;  48 2446-2453
    CrossrefPubMedGoogle Scholar
  • 62 Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications.  Diabetes Care. 1998;  21 1027
    PubMedGoogle Scholar
  • 63 Kanauchi M, Nishioka H, Dohi K. Serum levels of advanced glycosylation end products in diabetic nephropathy.  Nephron. 2001;  89 228-230
    CrossrefPubMedGoogle Scholar
  • 64 Wautier M P, Massin P, Guillausseau P J, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier J L. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. (Abstract).  Diabetes Metab. 2003;  29 44-52
    CrossrefPubMedGoogle Scholar
  • 65 Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R, Nagy J. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.  Am J Kidney Dis. 2001;  38 785-791
    CrossrefPubMedGoogle Scholar
  • 66 Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction.  Diabetes. 1999;  48 1842-1849
    PubMedGoogle Scholar
  • 67 Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.  Diabetologia. 2000;  43 1385-1388
    CrossrefPubMedGoogle Scholar
  • 68 Koschinsky T, He C J, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.  Proc Natl Acad Sci USA. 1997;  94 6474-6479
    CrossrefPubMedGoogle Scholar
  • 69 Pettersson-Fernholm K, Forsblom C, Hudson B I, Perola M, Grant P J, Groop P H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.  Diabetes. 2003;  52 891-894
    PubMedGoogle Scholar
  • 70 Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving HH, Cambien F. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients.  Diabetes. 2001;  50 1214-1218
    PubMedGoogle Scholar
  • 71 Matsunaga-Irie S, Maruyama T, Yamamoto Y, Motohashi Y, Hirose H, Shimada A, Murata M, Saruta T. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients.  Diabetes Care. 2004;  27 303-307
    PubMedGoogle Scholar
  • 72 Davis B J, Forbes J M, Thomas M C, Jerums G, Burns W C, Kawachi H, Allen T J, Cooper M E. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.  Diabetologia. 2004;  47 89-97
    CrossrefPubMedGoogle Scholar
  • 73 Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.  Diabetes. 1991;  40 1328-1334
    PubMedGoogle Scholar
  • 74 Azal O, Yonem A, Guler S, Cakir B, Baydar A, Corakci A, Kutlu M. Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.  Diabetes Obes Metab. 2002;  4 75-79
    PubMedGoogle Scholar
  • 75 Yamauchi A, Takei I, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, Ishii T, Koike T, Saruta T. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats.  Diabetes Res Clin Pract. 1997;  34 127-133
    CrossrefPubMedGoogle Scholar
  • 76 Osicka T M, Yu Y, Panagiotopoulos S, Clavant S P, Kiriazis Z, Pike R N, Pratt L M, Russo L M, Kemp B E, Comper W D, Jerums G. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.  Diabetes. 2000;  49 87-93
    PubMedGoogle Scholar
  • 77 Agardh C D, Stenram U, Torffvit O, Agardh E. Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats.  J Diabetes Compl. 2002;  16 395-400
    PubMedGoogle Scholar
  • 78 Oturai P S, Rasch R, Hasselager E, Johansen P B, Yokoyama H, Thomsen M K, Myrup B, Kofoed-Enevoldsen A, Deckert T. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats.  APMIS. 1996;  104 259-264
    PubMedGoogle Scholar
  • 79 Osicka T M, Yu Y, Lee V, Panagiotopoulos S, Kemp B E, Jerums G. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.  Clin Sci (Lond). 2001;  100 249-257
    PubMedGoogle Scholar
  • 80 Huang Y, Lin S, Zhou J. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue. (Abstract).  Chin Med J (Engl ). 1998;  111 698-704
    PubMedGoogle Scholar
  • 81 Booth A A, Khalifah R G, Todd P, Hudson B G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways.  J Biol Chem. 1997;  272 5430-5437
    CrossrefPubMedGoogle Scholar
  • 82 Degenhardt T P, Alderson N L, Arrington D D, Beattie R J, Basgen J M, Steffes M W, Thorpe S R, Baynes J W. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.  Kidney Int. 2002;  61 939-950
    CrossrefPubMedGoogle Scholar
  • 83 Alderson N L, Chachich M E, Frizzell N, Canning P, Metz T O, Januszewski A S, Youssef N N, Stitt A W, Baynes J W, Thorpe S R. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.  Diabetologia. 2004;  47 1385-1395
    PubMedGoogle Scholar
  • 84 Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation.  Diabetes. 1997;  46 895-899
    PubMedGoogle Scholar
  • 85 Figarola J L, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.  Diabetologia. 2003;  46 1140-1152
    CrossrefPubMedGoogle Scholar
  • 86 Soulis T, Sastra S, Thallas V, Mortensen S B, Wilken M, Clausen J T, Bjerrum O J, Petersen H, Lau J, Jerums G, Boel E, Cooper M E. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes.  Diabetologia. 1999;  42 472-479
    CrossrefPubMedGoogle Scholar
  • 87 Oturai P S, Christensen M, Rolin B, Pedersen K E, Mortensen S B, Boel E. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats.  Metabolism. 2000;  49 996-1000
    CrossrefPubMedGoogle Scholar
  • 88 Shoda H, Miyata S, Liu B F, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M. Inhibitory effects of tenilsetam on the Maillard reaction.  Endocrinology. 1997;  138 1886-1892
    CrossrefPubMedGoogle Scholar
  • 89 Flyvbjerg A, Denner L, Schrijvers B F, Tilton R G, Mogensen T H, Paludan S R, Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice.  Diabetes. 2004;  53 166-172
    PubMedGoogle Scholar
  • 90 Schwedler S B, Verbeke P, Bakala H, Weiss M F, Vilar J, Depreux P, Fourmaintraux E, Striker L J, Striker G E. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice.  Diabetes Obes Metab. 2001;  3 230-239
    CrossrefPubMedGoogle Scholar
  • 91 Forbes J M, Soulis T, Thallas V, Panagiotopoulos S, Long D M, Vasan S, Wagle D, Jerums G, Cooper M E. Renoprotective effects of a novel inhibitor of advanced glycation.  Diabetologia. 2001;  44 108-114
    CrossrefPubMedGoogle Scholar
  • 92 Wilkinson-Berka J L, Kelly D J, Koerner S M, Jaworski K, Davis B, Thallas V, Cooper M E. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.  Diabetes. 2002;  51 3283-3289
    PubMedGoogle Scholar
  • 93 Bolton W K, Cattran D C, Williams M E, Adler S G, Appel G B, Cartwright K, Foiles P G, Freedman B I, Raskin P, Ratner R E, Spinowitz B S, Whittier F C, Wuerth J P. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.  Am J Nephrol. 2004;  24 32-40
    CrossrefPubMedGoogle Scholar
  • 94 Thornalley P J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.  Arch Biochem Biophys. 2003;  419 31-40
    CrossrefPubMedGoogle Scholar
  • 95 McGill J B, Williams M E, Degenhardt T P, Szabo J R, Scotzinger R J. A Phase 2 Clinical Investigation of Pyridoxamine (Pyrdorin) in Type 1 and Type 2 Diabetic Patients with Overt Diabetic Nephropathy (PYR-205/207). (Abstract).  J Am Soc Nephrol. 2004;  15 565A
    PubMedGoogle Scholar

Allan Flyvbjerg, M. D., D.M.Sc

The Medical Research Laboratories · Clinical Institute · Medical Department M (Diabetes and Endocrinology) · Aarhus University Hospital

Nørrebrogade 44 · DK-8000 Aarhus C · Denmark

Phone: +45 89 49 21 61

Fax: +45 86 56 00 87

Email: allan.flyvbjerg@dadlnet.dk

      >